Oncology News | pharmaphorum

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

Cellectis rockets on gene-editing alliance with AstraZeneca

Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial com

News

Merck signs €1.4bn cancer alliance with China’s Hengrui

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

FDA clears Servier's Tibsovo as first targeted drug for MDS

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F

Imfinzi faces Keytruda competition in biliary tract cancer

Cellectis rockets on gene-editing alliance with AstraZeneca

Merck signs €1.4bn cancer alliance with China’s Hengrui

GSK claims a first with Jemperli in endometrial cancer

ESMO: J&J’s Tagrisso challenge, and other highlights

FDA clears Servier's Tibsovo as first targeted drug for MDS

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks